Gilead Sciences (GILD -0.53%) reports earnings on July 23. According to Bloomberg, analysts are estimating over $2.8 billion in sales. But remember that analysts were off -- off by a lot! -- last quarter in guessing sales, with Gilead's $2.3 billion in Sovaldi sales crushing their expectations. Could Gilead surprise to the upside again? Watch the video below for our take.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sovaldi beat analyst expectations last quarter -- could it again?
David Williamson owns shares of Johnson & Johnson and AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Gilead Sciences
GILD
$108.22
(-0.53%)
$0.58
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Does This Move Make Merck Stock a Buy?
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.